Welcome to our dedicated page for Novocure news (Ticker: NVCR), a resource for investors and traders seeking the latest updates and insights on Novocure stock.
NovoCure (NVCR) is a leader in developing innovative Tumor Treating Fields (TTFields) therapy for solid tumor cancers, offering non-invasive treatment alternatives through its proprietary medical devices. This page provides investors and healthcare professionals with essential updates on clinical advancements, regulatory milestones, and strategic initiatives shaping the oncology sector.
Access real-time press releases, earnings reports, and partnership announcements to stay informed about NVCR's progress in TTFields technology. Our curated collection includes updates on global clinical trials, FDA submissions, and peer-reviewed research findings critical for evaluating the company's market position.
Explore detailed coverage of financial performance, product innovations, and collaborations with leading cancer research institutions. Bookmark this page for streamlined access to NVCR's latest developments, ensuring you never miss pivotal updates in this dynamic field of oncology treatment.
Novocure (NASDAQ: NVCR) has announced the recipients of the 3rd Annual AACR-Novocure Grants for Tumor Treating Fields Research program, allocating over $2 million towards innovative cancer research. This grant initiative, in partnership with the American Association for Cancer Research (AACR), aims to enhance knowledge of Tumor Treating Fields (TTFields) and their application in cancer treatment. Notable recipients include Professor Maurizio D'Incalci, who will explore TTFields' impact on malignant pleural mesothelioma. The program includes six research grants and two career development awards, with funding ranging from $100,000 to $250,000.
Novocure (NASDAQ: NVCR) will report its second quarter 2021 financial results on July 29, 2021, before U.S. markets open. A conference call will follow at 8 a.m. EDT, where management will discuss the results for the three and six months ending June 30, 2021. Domestic callers can join by dialing 855-442-6895, while international callers can use 509-960-9037 with conference ID 1926805. All materials related to the event will be accessible on Novocure's investor relations website for at least 14 days after the call.
Novocure (NASDAQ: NVCR) reported final results from its phase 2 HEPANOVA trial for treating advanced hepatocellular cancer using Tumor Treating Fields (TTFields) with sorafenib. The trial showed a 76% disease control rate and 9.5% objective response rate in 21 evaluable patients, surpassing historical controls. Among patients completing 12 weeks of TTFields, the disease control rate rose to 91%. The data will be presented at the ESMO World Congress. Novocure plans a randomized controlled trial to further explore TTFields and its combination with immunotherapy.
Novocure (NASDAQ: NVCR) has initiated a clinical usability study for a new flexible torso array designed to enhance patient comfort during treatment. This updated array aims to improve skin adhesion, motion, and reduce irritation, with the study expected to conclude in Q3 2021. Alongside this, Novocure has launched MyLink™, allowing patients to download usage data, and a second-generation Tumor Treating Fields generator aimed at improving portability for torso patients. The company emphasizes its commitment to innovation and enhancing patient quality of life.
Novocure (NASDAQ: NVCR) has entered a clinical trial collaboration with GT Medical Technologies to explore the combination of Tumor Treating Fields (TTFields) and GammaTile Therapy for treating recurrent glioblastoma (GBM). This phase 2 pilot study aims to enroll around 55 patients in the U.S., focusing on progression-free survival as the primary endpoint. The collaboration seeks to establish the effectiveness of TTFields in enhancing the outcomes of radiation therapy, potentially improving survival rates for recurrent GBM patients.
Novocure (NASDAQ: NVCR) has announced FDA approval for its Investigational Device Exemption (IDE) supplement, which reduces the enrollment requirement for the LUNAR trial to 276 patients over 12 months. This phase 3 trial investigates the efficacy of Tumor Treating Fields in combination with immune checkpoint inhibitors or docetaxel for stage 4 NSCLC patients post-platinum therapy. The independent data monitoring committee recommended the adjustments based on an interim analysis, claiming no increased systemic toxicity. Final data is expected in 2022.
Novocure reported its Q1 2021 financial results, showing net revenues of $134.7 million, a 32% increase from Q1 2020. Gross profit rose 40% to $108.3 million, with a gross margin of 80%. However, the company experienced a net loss of $4.1 million, compared to a net income of $4.0 million in the previous year. Active patients rose 12% to 3,454, and prescription volumes remained stable. Novocure's ongoing clinical trials include pivotal studies for lung cancer and advanced liver cancer.
Novocure (NASDAQ: NVCR) has received FDA approval for its investigational device exemption (IDE) application to start the KEYNOTE-B36 trial, evaluating Tumor Treating Fields (TTFields) in combination with pembrolizumab for first-line treatment of advanced PD-L1 positive non-small cell lung cancer (NSCLC). The trial aims to enroll around 66 patients, focusing on objective response rate as the primary endpoint. Esteemed experts will guide enrollment and study execution. TTFields, an innovative therapy disrupting cancer cell division, is currently investigational for lung cancer.
Novocure (NASDAQ: NVCR) announced an update on the phase 3 LUNAR trial evaluating Tumor Treating Fields (TTFields) for stage 4 non-small cell lung cancer (NSCLC) after platinum failure. An independent data monitoring committee (DMC) recommended accelerating the interim analysis due to sufficient data from 210 patients. The DMC found no increased systemic toxicity and advised reducing the sample size to about 276 patients, which could expedite trial completion by over a year. Novocure plans to submit a protocol amendment to the FDA to incorporate these adjustments.
Novocure (NASDAQ: NVCR) announced 26 presentations at the AACR Annual Meeting 2021, highlighting the versatility of Tumor Treating Fields (TTFields) across various solid tumor types, including glioblastoma. Key findings include enhanced anti-tumor immunity and potential for combination therapies. Dr. Uri Weinberg emphasized the importance of ongoing research in understanding TTFields' role in cancer treatment. The research demonstrated that TTFields could disrupt cancer cell division, supporting its use alongside existing therapies.
